RARA and colorectal carcinoma: [35, 36, 37] However, there are also patient‐specific neoantigens that can be predicted by bioinformatics software such as HLAMiner and Polysolver.[38] For instance, TSHZ3‐L523P, RARA‐R83H, TP53‐R248W, EYA2‐V333I, and NRAS‐G12D specific‐patient neoantigens were predicted to induce NRT antitumor responses in CRC.[19] Although neoantigens are potential targets for personalized vaccines and NRT therapy, most neoantigen‐targeted therapies are customized and costly.